(Total Views: 570)
Posted On: 11/25/2024 7:19:11 PM
Post# of 148866
GSK angle?
Dr. J was Pi on GSK's inital CCR5 trial many years ago.
2021 Cytodyn hired previous 30 years @ GSK, biostatistics guy.
ViiV owns one of the two LL-PLS mutation bNab's.
Max came from ViiV.
GSK owns 75% of ViiV.
Melissa came from working with 2 prior GSK world-wide executives.
Dr. Pestell worked with a prior GSK world-wide executive.
GSK will build a single drug mfgr'ing site, as did for Max's drug.
GSK does buy single drugs, with very good terms.
I forget the 3 recent examples of few months ago.
Oct. 2024 example GSK does buy Phase one drugs:
https://www.gsk.com/en-gb/media/press-release...osciences/
My bet has been it's a matter of Cytodyn choosing right now not to execute a "low-ball", winner takes the patented, unprecedented safe, CCR5 axis control, offer.
Some other kinds of deals.
Not a take all just yet.
Dr. J was Pi on GSK's inital CCR5 trial many years ago.
2021 Cytodyn hired previous 30 years @ GSK, biostatistics guy.
ViiV owns one of the two LL-PLS mutation bNab's.
Max came from ViiV.
GSK owns 75% of ViiV.
Melissa came from working with 2 prior GSK world-wide executives.
Dr. Pestell worked with a prior GSK world-wide executive.
GSK will build a single drug mfgr'ing site, as did for Max's drug.
GSK does buy single drugs, with very good terms.
I forget the 3 recent examples of few months ago.
Oct. 2024 example GSK does buy Phase one drugs:
https://www.gsk.com/en-gb/media/press-release...osciences/
My bet has been it's a matter of Cytodyn choosing right now not to execute a "low-ball", winner takes the patented, unprecedented safe, CCR5 axis control, offer.
Some other kinds of deals.
Not a take all just yet.
(8)
(0)Scroll down for more posts ▼
